Clinical Roundup UVA scientists use AI to improve success rate for new drugs, reduce costs April 03, 2026Vol.52 No.13
Clinical Roundup Small molecule inhibitor blocks prostate cancer bone metastasis April 03, 2026Vol.52 No.13
Drugs & Targets FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients April 03, 2026Vol.52 No.13
Drugs & Targets FDA grants priority review to Elevar Therapeutics’s lirafugratinib as second-line cholangiocarcinoma treatment April 03, 2026Vol.52 No.13
PodcastThe Directors The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes March 27, 2026Vol.52 No.12By Sara Willa Ernst and Paul Goldberg
Trials & Tribulations In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt March 27, 2026Vol.52 No.12By Richard M. Goldberg
Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings? March 27, 2026Vol.52 No.12By Sara Willa Ernst
Cancer Policy FDA issues warning letter to ImmunityBio over misleading claims about cancer drug March 27, 2026Vol.52 No.12By Claire Marie Porter
